EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Effectiveness of tocilizumab for IgA vasculitis associated with idiopathic multicentric Castleman’s disease: Two cases and literature review

Koji Suzuki iD, Koichi Saito iD, Mitsuhiro Akiyama iD, Akari Miwa, Kanako Shimanuki iD, Kazuoto Hiramoto, Jun Kikuchi iD, Yuko Kaneko iD

Modern Rheumatology Case Reports · 2026

DOI: 10.1093/mrcr/rxag014 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2026. Verfasst von Koji Suzuki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Castleman Disease, Antibodies, Monoclonal, Humanized, Immunoglobulin A, Vasculitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic multicentric Castleman’s disease (iMCD) is a systemic lymphoproliferative disorder characterised by interleukin (IL)-6 overproduction. To date, several cases of iMCD with autoimmune features have been reported, and cases of iMCD complicated by IgA vasculitis have also been reported. IL-6 is reported to promote the production of galactose-deficient IgA1, a key pathogenic factor in IgA vasculitis. Therefore, IL-6 overproduction in iMCD may contribute to the development of IgA vasculitis in these cases. Here, we present two cases of iMCD complicated by IgA vasculitis, both successfully treated with tocilizumab, an IL-6 receptor blockade. Furthermore, our literature review identified two reported cases of iMCD complicated by IgA nephropathy, and one case of iMCD complicated by IgA vasculitis, all of which responded favourably to tocilizumab. Our cases and literature review suggest the pathogenic role of IL-6 in the development of IgA vasculitis in iMCD and the effectiveness of tocilizumab as a potential therapeutic option not only for iMCD itself, but also for IgA vasculitis in the setting of iMCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Castleman DiseaseAntibodies, Monoclonal, HumanizedImmunoglobulin AVasculitisHumansFemaleMaleTreatment OutcomeMiddle AgedInterleukin-6Adult

Stichwörter der Autor:innen

IgA vasculitisMulti-centric Castleman’s diseaseinterleukin-6tocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedImmunoglobulin AInterleukin-6

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Department of General Internal Medicine and Rheumatology, Gifu Municipal Hospital, Gifu, Japan.

ORCID-Profile: Koji Suzuki, Koichi Saito, Mitsuhiro Akiyama, Kanako Shimanuki, Jun Kikuchi, Yuko Kaneko

Zitieren

APA

Suzuki, K., Saito, K., Akiyama, M., Miwa, A., Shimanuki, K., Hiramoto, K., Kikuchi, J., & Kaneko, Y. (2026). Effectiveness of tocilizumab for IgA vasculitis associated with idiopathic multicentric Castleman’s disease: Two cases and literature review. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxag014

Vancouver

Suzuki K, Saito K, Akiyama M, Miwa A, Shimanuki K, Hiramoto K, et al. Effectiveness of tocilizumab for IgA vasculitis associated with idiopathic multicentric Castleman’s disease: Two cases and literature review. Modern Rheumatology Case Reports. 2026. doi:10.1093/mrcr/rxag014

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Koji and Saito, Koichi and Akiyama, Mitsuhiro and Miwa, Akari and Shimanuki, Kanako and Hiramoto, Kazuoto and Kikuchi, Jun and Kaneko, Yuko},
  title = {Effectiveness of tocilizumab for IgA vasculitis associated with idiopathic multicentric Castleman’s disease: Two cases and literature review},
  journal = {Modern Rheumatology Case Reports},
  year = {2026},
  doi = {10.1093/mrcr/rxag014}
}
Kostenlos starten →